Table 3.
New oral SERDs in clinical development
| SERD | Development phase | Metastatic breast cancer |
Early breast cancer |
||
|---|---|---|---|---|---|
| Compared to ET after CDK 4/6 inhibitors | Combination with CDK 4/6 inhibitors first line | Preoperative | Adjuvant | ||
| Elacestrant | III | NCT03778931 (EMERALD) results available | NCT04797728 (ELIPSE) | ||
| Amcenestrant (SAR-439859) | III | NCT04059484 (AMEERA-3) results available | NCT04478266 (AMEERA-5) | NCT04191382 (AMEERA-4) | NCT05128773 (AMEERA-6) |
| Camizestrant (AZD-9833) | III | NCT04214288 (SERENA-2) results available | NCT047111252 (SERENA-4) NCT04964934 (SERENA-6) |
||
| Giredestrant (GDC-9545) | III | NCT04576455 (acelERA) results available | NCT04546009 (persevERA) |
NCT04436744 (coopERA) NCT03916744 |
NCT04961996 (lidERA) |
| Imlunestrant (LY-3484356) | III | NCT04975309 (EMBER-3) | NCT04647487 (EMBER-2) | ||
| Rintodestrant (G1T48) | I | ||||
| LSZ 102 | I | ||||
CDK 4/6, cyclin-dependent kinase 4 and 6; ET, endocrine therapy; SERDs, selective estrogen receptors degraders.